Rensselaer Polytechnic Institute

Nuvo Research Inc.

University of Houston System

University of Pennsylvania

Health Research, Inc.

Crescita Therapeutics Inc.

Pankaj Sakharam Karande

Samir M Mitragotri

John Michael Newsam

Edward Thomas Kisak

Dominic King-Smith

Georges Belfort

Wade Hull

Jeffrey D Rimer

C Seth Pearson

Kathleen A McDonough

Jun Ha Kwak

Zachary Andrew Kloos

Brian Murray

Xiaowei Xu

Alain H Rook

Ngoc Truc-Chi Vo

Tejas Desai

Shujing Liu

Disclosed herein are novel anti-microbial peptides with inhibitory activity againstandbacteria. Additionally, a method for designing novel anti-microbial peptides is disclosed.

Anti-microbial peptides and method for designing novel anti-microbial peptides

Compositions and methods for treatment of viral skin disease, precancerous and cancerous skin disease, and other neoplasms are disclosed.

Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions

In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides. Such a method may comprise designing a peptide library of potential calcium oxalate inhibiting peptides; screening the peptide library for high efficacy inhibitor peptides for inhibition of calcium oxalate monohydrate crystallization; and conducting molecular characterization of the high efficacy inhibitor to determine specificity.

Peptide inhibitors of calcium oxalate monohydrate crystallization and uses thereof

The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.

Topical formulations for treating skin conditions

The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.

Topical formulations, systems and methods

It has been discovered that certain combinations of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) an active agent selected from at least one of lidocaine and tetracaine; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.

Topical formulation

It has been discovered that certain combinations compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) at least one active agent; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.

Growing community of inventors

Troy, NY, United States of America

Pankaj Sakharam Karande